Pulmonary Tuberculosis Clinical Trial
Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy.
Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy. The propose of this work was to evaluate the production of IFN- γ in cell supernatants of peripheral blood mononuclear cells (PBMC) culture, TNF-α, IL-10 and TGF-b in cell supernatants of monocytes (MO) culture and biochemical (total proteins, albumin, globulin, α-1-acid glycoprotein and C-reactive protein) and hematological (VHS) serum parameters before and after 3 and 6 months of therapy ;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02736864 -
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae
|
N/A | |
| Not yet recruiting |
NCT04055441 -
A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
|
||
| Completed |
NCT02349841 -
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
|
Phase 2 | |
| Completed |
NCT01927159 -
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT01691534 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
|
Phase 2 | |
| Completed |
NCT00803322 -
Improving Community Based Tuberculosis Care in Ethiopia
|
Phase 4 | |
| Completed |
NCT00834353 -
Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
|
N/A | |
| Withdrawn |
NCT03277742 -
Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
|
N/A | |
| Completed |
NCT00057434 -
Vitamin A Therapy for Tuberculosis
|
Phase 3 | |
| Not yet recruiting |
NCT06192160 -
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2 | |
| Recruiting |
NCT06127641 -
Rehabilitation of People With Post-tuberculosis Lung Disease
|
N/A | |
| Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
| Completed |
NCT04550832 -
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
|
Phase 2 | |
| Completed |
NCT02912832 -
Prospective Assessment of TBDx Feasibility
|
N/A | |
| Completed |
NCT01215851 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)
|
Phase 2 | |
| Recruiting |
NCT01503099 -
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
|
N/A | |
| Completed |
NCT04608955 -
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
|
Phase 2 | |
| Recruiting |
NCT05046366 -
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
|
||
| Completed |
NCT05896930 -
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
|
Phase 2 | |
| Completed |
NCT02279875 -
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
|
Phase 2 |